AstraZeneca Plc (NASDAQ:AZN) has reportedly warned that it might relocate its vaccine manufacturing site from Merseyside, U.K., to Philadelphia amid stalled negotiations with the U.K.’s Labour government.
The deadlock revolves around a reduction in state aid initially promised by the previous Conservative administration. The government wants to cut financial support for AstraZeneca’s vaccine facility from nearly $118 million (90 million pounds) to 40 million pounds.
Also Read: FDA Approves AstraZeneca’s Blockbuster Cancer Drug, Imfinzi, In Combination With Chemo For Non-Small Cell Lung Cancer.
The initial package included up to 70 million pounds in grants to develop an existing AstraZeneca vaccine facility at Speke and 20 million pounds for research and development from the U.K. Health ...
